Latest news with #CorceptTherapeuticsInc
Yahoo
7 days ago
- Business
- Yahoo
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...
Release Date: May 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Corcept Therapeutics Inc (NASDAQ:CORT) reported a revenue increase to $157.2 million in Q1 2025, up from $146.8 million in the same quarter last year. The company is confident in its future growth prospects, with a significant increase in the prescriber base and patient growth for hypercortisolism treatments. Corcept Therapeutics Inc (NASDAQ:CORT) has expanded its sales force significantly, from 60 to 125 clinical specialists, with plans to reach 175 by year-end. The company's Catalyst study showed that 1 in 4 patients with difficult-to-control diabetes have hypercortisolism, highlighting a significant market opportunity. Corcept Therapeutics Inc (NASDAQ:CORT) is advancing its oncology portfolio, with positive results from the Rosella trial in platinum-resistant ovarian cancer, showing a 30% reduction in disease progression risk. Net income decreased to $20.5 million in Q1 2025 from $27.8 million in the same quarter last year. The company faced operational challenges with its pharmacy vendor, affecting Q1 results due to insufficient capacity to handle increased prescription volumes. A transition to authorized generic tablets, which have a lower net price, led to a 13% decrease in average price per tablet. Corcept Therapeutics Inc (NASDAQ:CORT) is involved in ongoing patent litigation with TEA, which could impact future market dynamics. The company's ALS trial did not meet its primary endpoint, although there was an observed improvement in overall survival, indicating potential regulatory challenges. Warning! GuruFocus has detected 7 Warning Signs with CORT. Q: Can you explain where Relacorilant fits into the treatment paradigm for ovarian cancer, and how it compares to other treatments like Elaheir? A: Roberto Viera, President of the Oncology Division, explained that Relacorilant is poised to become a new standard of care in platinum-resistant ovarian cancer. The treatment landscape is fragmented, and Relacorilant offers a new option in multiple lines of therapy, including before or after biomarker-driven agents like Elaheir. Q: With the improvements in March and April, how will this affect revenue projections for the upcoming quarters? A: Sean Maduk, President of the Endocrinology Division, stated that the fundamentals of the business are strong, and growth is expected to continue and accelerate throughout the year. The company is confident in achieving its revenue guidance of $900 to $950 million. Q: What is the mix between branded and authorized generic business for Korlym, and how does it affect revenue projections? A: Sean Maduk noted that over half of the product is currently on the authorized generic, and this percentage is expected to increase. Future volume growth is expected to outweigh any price changes due to the mix of products. Q: Are you expecting an advisory committee meeting for Relacorilant's NDA? A: Charlie Robb, Chief Business Officer, stated that they do not expect an advisory committee meeting, as it was not required for Korlym or other recently approved drugs in hypercortisolism. Q: What corrective measures did the pharmacy vendor take to improve operations, and can they meet future demand? A: Sean Maduk explained that the pharmacy vendor addressed staffing issues that led to prescription delays. The vendor has since improved operations, and the company is exploring broader distribution networks for future products like Relacorilant. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
San Francisco Chronicle
05-05-2025
- Business
- San Francisco Chronicle
Corcept: Q1 Earnings Snapshot
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Monday reported first-quarter net income of $20.3 million. The Redwood City, California-based company said it had net income of 17 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for earnings of 17 cents per share. The drug developer posted revenue of $157.2 million in the period, missing Street forecasts. Four analysts surveyed by Zacks expected $178 million. _____
Yahoo
01-05-2025
- Business
- Yahoo
Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?
We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take a look at where Corcept Therapeutics Inc. (NASDAQ:CORT) stands against other growth stocks to buy for the next 3 years. On April 29, Dan Ives of Wedbush Securities joined 'Power Lunch' on CNBC to discuss his outlook for the tech sector and expressed that tariffs aren't stopping the AI revolution. According to Ives, the critical question for the sector was whether spending, particularly CapEx, was being maintained. He expressed confidence that CapEx was holding up and predicted that the forthcoming results from big tech companies would serve more as a confidence booster for the market, rather than fueling the existing fears. As some investors are of the idea that concerns about a potential soft patch in the economy remain, there's a preference for safer investments in insurance and other stable sectors, rather than big tech. However, Ives acknowledged that while uncertainty had been prevalent in recent weeks, his own survey work and field research indicate that AI-related spending stays strong. He noted that, while there were areas of the cloud sector where spending was accelerating, the overall uncertainty would likely result in broad guidance ranges from companies. Michael Darda, the Managing Director, Chief Economist, and Macrostrategist at ROTH, also believes that AI would generate solid returns in the future. Ives agreed with Darda's assessment and stated that enterprises were seeing similar advancements and could not afford to leave their AI projects behind without the risk of consequently falling behind. He also pointed out that for companies like those in the MAG7, the AI revolution is a central theme, which is why challenges brought forward by tariffs would not impact the AI revolution as much. Darda changed his outlook from bearish to bullish on tech and AI recently due to his personal experience with AI tools, which he felt had improved over the past year. Dan Ives reiterated that, despite the uncertainty created by tariffs, the demand for software remained a safety blanket, and spending by hyperscale companies is expected to continue. Our Methodology We sifted through financial media reports to compile a list of the top growth stocks to buy for the next 3 years. We then selected 15 stocks with a 3-year revenue compound annual growth rate of over 20%. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024, which was sourced from Insider Monkey's database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. 3-Year Revenue CAGR: 22.64% Number of Hedge Fund Holders: 29 Corcept Therapeutics Inc. (NASDAQ:CORT) discovers and develops medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US. The company's primary revenue and growth driver is its Cushing's syndrome franchise, which is centered around its drug called Korlym. In 2024, the Cushing's syndrome segment made $675 million in revenue, which was up 40% year-over-year. This came from a record number of new Korlym prescribers and patients throughout 2024, indicating increasing physician awareness of hypercortisolism's prevalence. Corcept is solidifying its position in the Cushing's syndrome market by developing and potentially launching relacorilant. This is a proprietary selective cortisol modulator. Corcept submitted an NDA for relacorilant on December 30, 2024, based on compelling data from its Phase III GRACE and Phase II studies. These studies showed statistically significant improvements in hypertension, hyperglycemia, weight, and other Cushing's symptoms, with a favorable safety profile. Corcept projects a 2025 revenue guidance of $900 to $950 million in this area. ClearBridge Small Cap Strategy stated the following regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its Q3 2024 investor letter: 'Another top contributor in health care, Corcept Therapeutics Incorporated (NASDAQ:CORT), saw its stock rise in the third quarter after strong earnings results and increased guidance for sales of Korlym, a hyperglycemia drug for adults with Cushing's syndrome, which investors had been concerned would be vulnerable to the launch of a competitor's generic version late last year. The company has seen added tailwinds from anticipation surrounding its next-generation version of the drug, which has fewer side effects, and is expected to release phase 3 data later this year and potentially file for FDA approval in 2025.' Overall, CORT ranks 15th on our list of the best growth stocks to buy for the next 3 years. While we acknowledge the growth potential of CORT, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CORT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
